Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Eli Lilly Launches Diabetes Education Tools In China

This article was originally published in PharmAsia News

Executive Summary

Eli Lilly, the International Diabetes Federation and Healthy Interactions Inc recently kicked off the Conversation Map program for diabetic patient education in Hangzhou. Launched in 37 countries by 2008, the popular global program employs conversation-based tools to enhance patients' self-management of diabetes. By interacting with the conversation map, patients can gain diabetes-related knowledge, find info on problems, form conclusions and change their lifestyle accordingly. This year, 500 hospitals in China will gradually implement the free program, with each organizing interactive activities between patients and physicians at least twice a month. It is estimated that millions of local diabetic patients will participate in the next two years. (Click here for more - Chinese Language)

Latest Headlines
See All
UsernamePublicRestriction

Register

SC071455

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel